Common Contracts
1 similar Institution Agreement contracts
Amendment No. 3 to the Institution Agreement dated 02 August 2010 for the Ponesimod study / AC- 058B202 between ACTELION Pharmaceuticals Ltd Gewerbestrasse 164123 Allschwil Switzerland(hereinafter “ACTELION”) andKrajská zdravotní, a.s. with seat...Institution Agreement • February 4th, 2019
Amendment No. 3 to the Agreement on conducting a clinical study / Dodatek č. 3 ke Smlouvě oprovedení klinické studie This Amendment No. 3 (the “Amendment”) to the Agreement on conducting a clinical study dated 02 August 2010 (the “Agreement”) for the clinical study conducted in accordance with the Protocol AC-058B202 titled: “Multicenter, randomized, double-blind, parallel-group extension to AC-058B201 to investigate the long-term safety, tolerability, and efficacy of 10, 20 and 40mg/day ACT- 128800, an oral S1P1 receptor agonist, in patients with relapsing-remitting multiple sclerosis” and following amendments: Amendment No. 1. entered on 29 June 2012 and Amendment No. 2. entered on 16 April 2015 thereto (the “Study”), has been concluded by and between: Tento Dodatek č. 3 (dále jen „Dodatek“) ke ke Smlouvě o provedení klinické studie ze dne 2. srpna 2010 (dále jen „Smlouva“) o klinickém hodnocení prováděném v souladu s Protokolem č. AC-058B202 nazvaným:„Multicentrické, randomizované,
